


Journal Pre-proof

COVID-19 symptoms are attenuated in moderate-to-severe atopic dermatitis patients treated with dupilumab

Benjamin Ungar, MD, Jacob W. Glickman, MD, Alexandra Golant, MD, Celina Dubin, BA, Olga Marushchak, MA, Alyssa Gontzes, BS, Daniela Mikhaylov, BA, Giselle K. Singer, BS, Danielle Baum, RN, Nancy Wei, BA, Antonio Sanin, BA, Diana Gruenstein, BA, Mark G. Lebwohl, MD, Ana B. Pavel, PhD, Emma Guttman-Yassky, MD, PhD



PII: S2213-2198(21)01203-4

DOI: <https://doi.org/10.1016/j.jaip.2021.10.050>

Reference: JAIP 3934

To appear in: *The Journal of Allergy and Clinical Immunology: In Practice*

Received Date: 19 July 2021

Revised Date: 9 September 2021

Accepted Date: 18 October 2021

Please cite this article as: Ungar B, Glickman JW, Golant A, Dubin C, Marushchak O, Gontzes A, Mikhaylov D, Singer GK, Baum D, Wei N, Sanin A, Gruenstein D, Lebwohl MG, Pavel AB, Guttman-Yassky E, COVID-19 symptoms are attenuated in moderate-to-severe atopic dermatitis patients treated with dupilumab, *The Journal of Allergy and Clinical Immunology: In Practice* (2021), doi: <https://doi.org/10.1016/j.jaip.2021.10.050>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology

Original Article

Title: COVID-19 symptoms are attenuated in moderate-to-severe atopic dermatitis patients treated with dupilumab

Authors: Benjamin Ungar, MD¹; Jacob W. Glickman, MD^{1*}; Alexandra Golant, MD^{1*}; Celina Dubin, BA¹; Olga Marushchak, MA^{1,2}; Alyssa Gontzes, BS¹; Daniela Mikhaylov, BA¹; Giselle K. Singer, BS¹; Danielle Baum, RN¹; Nancy Wei, BA¹; Antonio Sanin, BA¹; Diana Gruenstein, BA¹; Mark G. Lebwohl, MD¹; Ana B. Pavel, PhD^{1,3}; Emma Guttman-Yassky, MD, PhD¹

1. Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

2. Touro College of Osteopathic Medicine, New York, NY, USA.

3. Department of Biomedical Engineering, The University of Mississippi, University, MS, USA.

*Authors contributed equally

Corresponding author:

Emma Guttman-Yassky MD, PhD

Department of Dermatology and Laboratory of Inflammatory Skin Diseases

Icahn School of Medicine at Mount Sinai

5 E. 98th Street, New York, NY 10029 U.S.A.

Email: emma.guttman@mountsinai.org

Telephone: 212-241-9728/3288; Fax: 212-876-8961

24 **Abstract word count:** 247

25 **Word count:** 2,686

26 **IRB approval status:** Reviewed and approved by the Department of Dermatology at the Icahn
27 School of Medicine; approval protocols STUDY-20-00410 and STUDY 20-00682

28 **Funding:** This work was supported by the Department of Dermatology at the Icahn School of
29 Medicine at Mount Sinai and a grant from Regeneron and Sanofi. Patients were recruited from
30 within the Department of Dermatology at the Icahn School of Medicine. All funding sources
31 reviewed and accepted the study design and the manuscript, with minimal input from Regeneron
32 and Sanofi.

33 **Conflicts of interest:** Dr. Emma Guttman-Yassky is an employee of Mount Sinai and has
34 received research funds (grants paid to the institution) from Abbvie, Amgen, AnaptysBio,
35 AstraZeneca, Boehringer-Ingelhiem, Cara Therapeutics, Innovaderm, Janssen, KAO, Kyowa
36 Kirin, Leo Pharma, Pfizer, Regeneron Pharmaceuticals, Inc. and UCB; and is a consultant for
37 Abbvie, Almirall, Amgen, Arena, Asana Biosciences, AstraZeneca, Boehringer-Ingelhiem,
38 Bristol-Meyers Squibb, Cara Therapeutics, Connect Pharma, Eli Lilly, EMD Serono, Evidera,
39 Galderma, Ichnos Sciences, Incyte, Janssen Biotech, Kyowa Kirin, Leo Pharma, Pandion
40 Therapeutics, Pfizer, Ribon, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi,
41 SATO Pharmaceutical, Siolta Therapeutics, Target PharmaSolutions, UCB and Ventyx
42 Biosciences.

43 Dr. Mark Lebwohl is an employee of Mount Sinai and receives research funds from: Abbvie,
44 Amgen, Arcutis, Avotres, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly, Incyte, Janssen
45 Research & Development, LLC, Ortho Dermatologics, Regeneron, and UCB, Inc. Dr. Lebwohl
46 is also a consultant for Aditum Bio, Almirall, AltruBio Inc., AnaptysBio, Arcutis, Inc., Aristeia

Therapeutics, Arrive Technologies, Avotres Therapeutics, BiomX, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Dr. Reddy's Laboratories, Evelo Biosciences, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Helsinn Therapeutics, Hexima Ltd., LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Seanergy, and Verrica.

Dr. Alexandra Golant is an employee of Mount Sinai and receives honoraria from Regeneron, Sanofi Genzyme, AbbVie, Eli Lilly, UCB, Ortho Dermatologics, and Dermira. Dr. Golant is also a consultant for AbbVie and Pfizer.

All other authors have no conflicts of interest to disclose.

ABSTRACT

Background: In the SARS-CoV-2/COVID-19 pandemic, we need to understand the impact of immunomodulatory medications on COVID-19 symptom severity in patients with inflammatory diseases, including the Type 2/Th2 polarized skin disease, atopic dermatitis/AD.

Objective: Since it is believed that Type 1/Th1 immunity controls viral infections, and that there is a Th1/Th2 counter-regulation, we hypothesized that Th2 targeting with the IL-4R α -antagonist, dupilumab, in patients with moderate-to-severe AD rebalances Th1/Th2 axis, potentially leading to attenuated COVID-19 symptoms.

Methods: 1,237 moderate-to-severe AD patients in the Icahn School of Medicine at Mount Sinai Department of Dermatology were enrolled in a registry. Patients were screened for COVID-19-related symptoms and assigned a severity score (asymptomatic[0]-fatal[5]). Scores were compared among 3 treatment groups: dupilumab (n=632), other systemic treatments (n=107), and limited/no treatment (n=498). Demographic and comorbid covariates were adjusted by multivariate generalized logistic regression models.

Results: The dupilumab-treated group showed reduced incidence and severity of COVID-19 symptoms versus other treatment groups. Dupilumab-treated patients were less likely to experience moderate-to-severe symptoms versus patients on other systemics (p=0.01) and on limited/no treatment (p=0.04), and less likely to experience any symptoms versus patients on other systemics (p=0.01). This effect was seen in our entire cohort and in the subgroup of patients with verified COVID-19 or high-risk exposure.

Conclusions: Patients on dupilumab experienced less severe COVID-19 manifestations and lesser symptoms compared to patients on other systemics and on limited/no treatment. These

results suggest that Th2 modulation with dupilumab may have a protective effect on anti-viral immune response in AD patients.

Highlights box:

1. What is already known about this topic?

- Preliminary data suggest increased type 2 cytokines during the COVID-19 cytokine storm. However, it remains unclear how COVID-19 outcomes differ between AD patients on type 2-targeting agents (dupilumab) and those treated with other systemics or topical treatments.

2. What does this article add to our knowledge?

- This is the first study to directly compare the severity of COVID-19 symptoms in moderate-to-severe AD patients on different treatments, shedding important light on the treatment of AD patients during the pandemic and beyond.

3. How does this study impact current management guidelines?

- Our results suggest that type 2-targeting with dupilumab may attenuate COVID-19 responses, supporting the safety of specific type 2-targeting agents in AD patients during the COVID-19 pandemic, and potentially extending to other viral infections.

Key words: Atopic dermatitis; biologics; dupilumab; COVID-19; SARS-CoV-2; Th2

Abbreviations:

AD: Atopic dermatitis

EUA: Emergency Use Authorization

115 BMI: Body mass index
116 IFN: Interferon
117 IL: Interleukin
118 TNF: Tumor necrosis factor
119
120

Journal Pre-proof

INTRODUCTION

As of July, 2021, there have been more than 182 million cases of COVID-19 caused by the novel SARS-CoV-2 reported worldwide, leading to nearly 4 million deaths (1-3). Recently, due to extraordinary vaccine development efforts, the American Food and Drug Administration issued Emergency Use Authorizations (EUA) for three vaccines (4-6). Despite the advent of these vaccines, effective treatments are still a target for research and development efforts, with several therapies having been granted EUA (7). Furthermore, the risk of patients with inflammatory skin diseases to develop more symptomatic COVID-19 infection is unknown, particularly in context of immunomodulatory medications.

Previous research has shown that abnormally elevated Th2 cytokines may inhibit appropriate Th1 immune responses in the setting of viral exposure, impeding the reliance on Th1 signaling in initial responses to viral infections (8-11). This is especially relevant for atopic dermatitis (AD), a disease characterized primarily by Th2 skewing (12), with an increased susceptibility to viral infections (10). Moreover, elevated expression of Th2 cytokines in serum (e.g., IL-4, IL-10, and IL-13) was reported in patients with COVID-19, especially during the cytokine storm (2, 13-15).

Despite the greater risk for viral infections and the baseline Th2 polarization in AD, the risk for COVID-19 incidence and symptom severity in this common disease (~7% of the adult US population) (16), is still unknown. Determining COVID-19 risk profiles is particularly important in patients with moderate-to-severe AD on immunomodulatory medications. While some society guidelines recommend continuing these medications, there remains a dearth of evidence (17, 18). Recent case series and studies on some inflammatory conditions suggest that immunomodulatory medications may not change the risk of infection or symptomatology (19-

21). However, most of these reports were small-scale-studies or did not include AD. Furthermore, direct comparisons of COVID-19 outcomes between specific immunomodulatory drugs are lacking, making it difficult to draw conclusions about the comparative effects of different immunomodulatory medications.

Dupilumab, which inhibits the key Th2 cytokines IL-4 and IL-13, is the first FDA-approved treatment for moderate-to-severe AD, and is also approved for asthma and chronic rhinosinusitis with nasal polyps (22-24). While dupilumab has been shown to robustly modulate the Th2 pathway, it does not affect Th1 signaling (23, 25). Preliminary reports have not shown increased SARS-CoV-2 infection rates among patients treated with dupilumab (26-31). However, these limited studies did not compare dupilumab-treated patients with those on other treatments or not receiving systemic treatments. To date, no study has evaluated the effects of SARS-CoV-2 exposure and infection in AD patients on dupilumab compared to other therapeutics.

The present study is the first large-scale, prospective evaluation of 1,237 patients with moderate-to-severe AD treated with dupilumab, broad immunosuppressants, or those not receiving systemic treatments. This registry study aims to investigate whether targeting type 2 inflammation with dupilumab may protect against symptomatic SARS-CoV-2 infections in patients with AD. Our data show that patients on dupilumab were less likely to develop symptomatic COVID-19 infection compared to patients on other systemic treatments for AD.

METHODS

Patients

We performed a cross-sectional analysis of reported demographics, medical history, and medications from 1,237 moderate-to-severe AD patients enrolled from April 2nd 2020 through January 31st, 2021 in a prospective registry related to COVID-19 in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai. Patients were enrolled under institutional review board-approved consent, and the study was conducted according to the Declaration of Helsinki. The electronic medical record was queried for all related ICD10 codes and each patient chart was reviewed to ensure inclusion criteria were met. Patients were enrolled at the time of clinical visit, when applicable, or enrolled over the phone. Inclusion criteria included being older than 9 years of age with a diagnosis of moderate-to-severe atopic dermatitis, defined as currently or previously being on systemic therapy (including dupilumab, phototherapy, or oral immunomodulatory medications), or as candidates for systemic therapy.

Patients were asked about past medical history, medications, demographics (i.e., age, gender, and self-reported race), as well as the presence and duration of individual COVID-19-related symptoms, including objective or subjective fever, sore throat, cough, congestion, headache, fatigue, anosmia, dysgeusia, dyspnea, nausea, vomiting, diarrhea, anorexia, and skin changes. Based on the symptoms described, each patient was given a COVID-19 symptom severity score from 0-5: 0: “asymptomatic”; 1: “mild disease” (no fever, no dyspnea, resolving in <7 days, resembling a common cold); 2: “moderate disease” (some fever and/or cough, or other lower respiratory symptoms, resolving at home in 7-14 days); 3: “severe disease” (pneumonia, required hospitalization, but resolved without intubation); 4: “very severe disease” (required hospitalization, intubation, and other supportive measures); 5: “fatal.”

One thousand two-hundred and thirty-seven patients were included in the final analysis, out of 1,357 patients enrolled. In the final analysis, we excluded patients treated concomitantly with dupilumab and other systemic therapies (due to the hypothesis that dupilumab would reduce symptom severity compared to other systemic treatments), patients on dupilumab for <2 months (in order to allow for the proposed effects of dupilumab to manifest), and patients on additional immunomodulating therapies for other skin or extracutaneous indications besides AD (including TNF α and IL-23/IL-17 antagonists).

Statistical analysis

We powered our study based on the range of estimates for the incidence of SARS-CoV-2 infected patients at Mount Sinai Hospital. We assumed a positivity rate of 21% among 600 Mount Sinai Dermatology patients, with approximately n=100 SARS-CoV-2-infected patients on dupilumab and n=20 infected patients in the control group. Assuming an effect size of 25% (e.g. 30% patients with symptoms in the control group and 5% in the dupilumab group), a sample size of at least n=100 patients on dupilumab and n=20 controls is enough to detect statistically significant differences between groups with 85% power using a two-sided Fisher exact test with a Type I error $\alpha=0.05$. Assuming a sample size five times larger, such as n=500 infected patients on dupilumab and n=100 infected patients in the control group, would allow us to detect an effect size of 10% (e.g. 15% patients with symptoms in the control group and 5% in the dupilumab group) with 90% power using a two-sided Fisher exact test with a Type I error $\alpha=0.05$.

Demographic characteristics between groups were assessed using a two-sided Fisher exact test or ANOVA for categorical and continuous variables, respectively. The primary outcome for this report was the presence of moderate-to-severe COVID-19 symptoms in each treatment group,

with the secondary outcome being the incidence of any symptoms. Because of the potential for multiple confounders, we associated the presence of COVID-19-related symptoms with dupilumab treatment compared to other systemic treatments and with dupilumab treatment compared to limited/no treatments using multivariate logistic regression models. We adjusted for known or suspected COVID-19-related comorbidities (age, gender, race, hypertension, diabetes, body mass index [BMI], asthma, ACE-inhibitor usage). Using a similar approach, we also associated the presence of COVID-19-related symptoms with AD treatments by stratifying our cohort into a set of higher COVID-19-related risk patients with confirmed positive SARS-CoV-2 polymerase chain reaction (PCR) or COVID-19 serological tests, exposure to COVID-19-positive patients (diagnosed via PCR or serology) or to a person with COVID-19-related symptoms.

RESULTS

Patients grouped by AD treatment

Twelve-hundred, thirty-seven patients with moderate-to-severe AD were included in the analysis (age range 9-95 years). Patients were initially grouped based on their AD treatment: 632 patients on dupilumab, 107 patients on other systemic treatments, and 498 patients on limited or no treatment. The 107 patients on other systemics included 52 on phototherapy, 29 on oral JAK inhibitors, 14 on prednisone, 6 on methotrexate, 4 on cyclosporine, and 2 on mycophenolate mofetil. Among patients on limited or no treatment, 354 were on topicals and 153 had no treatment. Demographics, medication history, and comorbidities are listed in Table 1A. No significant differences were found between groups in terms of age and race.

COVID-19 symptom severity

We calculated the distribution of COVID-19 symptom severity across groups in six categories: 0/"asymptomatic," 1/"mild," 2/"moderate," 3/"severe," 4/"very severe," and 5/"fatal" (Table 1B). Our initial analysis focused on the entire cohort of patients, agnostic to laboratory evidence of COVID-19 infection. Treatment groups were compared to determine the proportions of patients in each symptom category (Figure 1). Given the potential for multiple confounders and risk factors for symptomatic infection (Table 1A) (32), we adjusted for known risk factors for increased COVID-19 morbidity (e.g., obesity, hypertension, etc.) using logistic regression models. We found that patients on dupilumab were less likely to experience moderate-to-severe symptoms compared to patients on other systemic treatments (OR=3.89; p=0.008, Table 2A). Furthermore, they were less likely to experience moderate-to-severe symptoms compared to those on limited/no treatments (OR=1.96; p=0.04; Table 2B). Additionally, BMI was

significantly associated with moderate-to-severe symptoms across COVID-19 related patients treated with biologic and systemic therapies ($p < 0.001$, Table 2A).

When evaluating the effects of various clinical variables on the presence of COVID-19-related symptoms, we found that non-biologic systemic treatment was significantly associated with symptomatology relative to treatment with dupilumab ($OR = 1.87$; $p = 0.01$, Table 2C). However, there were no differences in predicting symptomatology among patients on dupilumab relative to the limited/no treatment group (Table 2D).

Symptom severity in patients with confirmed COVID-19 diagnosis or exposure

Next, we compared the subgroup of patients comprised of those with a laboratory confirmed COVID-19 infection history based on PCR testing, or other antibody testing performed in a clinical context, or those with high-risk COVID-19 exposures, including to individuals with documented COVID-19 infection or with symptoms highly suspicious for COVID-19 infection ($n = 164$ for dupilumab, $n = 26$ for other systemics, $n = 116$ for limited/no treatment; Table 3; Figure 2). Similar to the previous logistic regression model results, non-dupilumab systemic treatment was significantly associated with moderate-to-severe symptoms relative to treatment with dupilumab ($OR = 13.79$; $p = 0.002$; Table 4A). Additionally, being on limited/no treatment was also significantly associated with moderate-to-severe symptoms relative to dupilumab ($OR = 2.44$; $p = 0.05$; Table 4B). BMI was a significant covariate of moderate-to-severe symptoms across all systemic treatment groups in this known infection/high-risk exposure group ($p = 0.005$; Table 4A).

In patients with known COVID-19 infection or high-risk exposure, being on non-dupilumab, systemic therapies was significantly associated with symptomatology relative to

267 being on dupilumab (OR=2.97; $p=0.03$, Table 4C). Similar to the entire cohort, there were also
268 no differences in predicting symptoms among high-risk exposure patients on dupilumab relative
269 to the limited/no treatment group (Table 4D).

270

Journal Pre-proof

DISCUSSION

The present study is the first large-scale, prospective evaluation of COVID-19 symptomatology in patients with moderate-to-severe AD, aiming to understand the effect of specific Th2 modulation with dupilumab compared with other systemic immunomodulators and to topical or no treatment. Understanding COVID-19 symptomatology in patients with moderate-to-severe AD in the context of immunomodulatory treatment is crucial, due to the long-term health consequences of SARS-CoV-2 infection, which are more substantial with moderate-to-severe symptomatology (33), as well as the massive economic burden on the United States hospital system from treating COVID-19 patients (34). Patients with moderate-to-severe AD are also particularly important to study in this context due to their increased susceptibility to viral infections and their robust Type 2/Th2 activation (10, 35). Since Type 1/Th1 immunity is considered to control viral responses, and there is a Th1/Th2 counter-regulation, we hypothesized that specific Th2 antagonism in patients with moderate-to-severe AD with the anti-IL-4R α , dupilumab, may rebalance the Th1/Th2 axis, potentially leading to attenuated COVID-19 symptomatology.

Our study found that dupilumab reduces both the incidence and severity of COVID-19 symptoms among AD patients, compared to both other systemic treatments and to no systemic treatments. We found that patients treated with dupilumab were less likely to experience moderate-to-severe symptoms compared to patients on other systemics ($p=0.01$) as well as to patients on limited/no treatment ($p=0.04$). Patients treated with dupilumab were also less likely to experience any symptoms at all compared to patients on other systemics ($p=0.01$). This relationship holds true for patients with suspected COVID-19, as well as for patients with a serologically confirmed COVID-19 diagnosis or a confirmed high-risk exposure. Those treated with dupilumab were less likely to experience moderate-to-severe symptoms compared to those

on other systemics ($p=0.002$) as well as on limited/no treatment ($p=0.05$) and were less likely to experience symptoms at all compared to patients on other systemics ($p=0.03$).

The robust effect of dupilumab on COVID-19 symptomatology may be due to primary modulation of Th2 pathway, without downregulation of Th1 immunity. This relationship between Th2 modulation and Th1/innate immune responses has been demonstrated in other atopic disease states, such as asthma (36). In one study, asthma patients treated with the Th2 modulator omalizumab (anti-IgE) had a lower incidence of respiratory virus-induced asthma exacerbations and a more robust IFN α response in vitro to rhinovirus stimulation (36). Similarly, our study found that COVID-19 symptoms and severity were reduced in dupilumab even when compared to limited/no treatment, suggesting that Th2 suppression may normalize the Th1/Th2 imbalance. Unlike dupilumab, broad acting immunosuppressants downregulate Th1 and other immune axes in addition to the pathogenic Th2 axis (23, 37-39), which may account for the significant differences in clinical outcomes as compared to dupilumab, which reduces incidence and severity of symptoms in COVID-19. These results hold even when adjusting for a number of clinical and demographic variables that may affect COVID-19 severity, including race, age, and BMI (32). Older age and higher BMI were significantly associated with more frequent and more severe symptoms, consistent with prior knowledge (32).

The main analysis in our study included all patients with a likely COVID-19 diagnosis, regardless of a laboratory-confirmed COVID-19 diagnosis. Thus, we acknowledge that some patients who reported probable COVID-19 symptoms may have had other infections (e.g. respiratory or gastrointestinal). However, we believe that this approach is crucial for several reasons: primarily, because there are likely many COVID-19 cases undiagnosed by formal testing in our cohort; testing was unreliable early on, and even now laboratory screening for

asymptomatic cases is not routinely performed. Further, including all subjects may contribute to eliminating biases in testing behavior, since symptomatic patients are more likely to get tested. Additionally, although the impetus for this study was to evaluate the impact of immunomodulatory drugs specifically on COVID-19 symptomatology, these data showing that Th2 modulation potentially ameliorates COVID-19 symptoms extends beyond the current era. Our findings may thus have implications for other common viral infections, such as influenza, and for possible future pandemics.

In the setting of the current COVID-19 pandemic, despite the advent of vaccination and increasing efforts to widely distribute vaccines to the population, it remains crucial to understand the impact of immunomodulatory medications in patients with chronic inflammatory diseases; many people may be unable or unwilling to get vaccines, the long-term protection offered by vaccines is still unknown, and the efficacy and duration of immune response to vaccination in the setting of immunomodulatory medications remains unknown. Because of this, we also performed an analysis focused on outcomes in patients with confirmed laboratory evidence of COVID-19 infection or with significant known COVID-19 exposures, and the results in this subset were even more significant than those found in the entire cohort.

We acknowledge some limitations in this study. Primarily, there are inherent limitations to a registry-based study, including sampling bias, recall bias, and patients being enrolled at a single timepoint. Our study was also limited by the fact that we could not obtain laboratory confirmation (via serology testing) of COVID-19 infection in many patients. Additional testing will provide even more evidence for the relevance of these findings to confirmed COVID-19 infection.

Future studies are needed to understand the implications of our findings for other specific viral conditions. Furthermore, biomarker-based studies may provide added support for the proposed mechanism by which Th2 blockade might produce the results seen in this study. Additionally, understanding the immune response to COVID-19 vaccination in patients on immunomodulatory medications will be crucial as vaccination becomes increasingly widespread. Lastly, further studies in other inflammatory conditions commonly treated with immunomodulatory medications will be needed as well. The present study is the first to demonstrate the significant protection potentially offered by Th2-targeting with dupilumab in reducing symptom incidence and severity compared to other treatments for AD in the context of COVID-19 infection. These findings have important implications, not only for the millions of moderate-to-severe AD patients in this country exposed to COVID-19 and other viral infections, but potentially for patients with chronic atopic and other conditions on immunomodulatory medications.

REFERENCES

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England journal of medicine*. 2020;382(18):1708-20.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
3. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis*. 2020;20(5):533-4.
4. ACIP Evidence to Recommendations for Use of Pfizer-BioNTech COVID-19 Vaccine under an Emergency Use Authorization [press release]. CDC.gov2020.
5. FDA grants authorization to Moderna's Covid-19 vaccine, the second in the U.S. [press release]. STAT News2020.
6. Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee [press release]. JnJ.com2021.
7. NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. In: NIH, editor. 2021.
8. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. *The Journal of clinical investigation*. 2004;113(5):651-7.
9. Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J, Keadze T, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. *Proc Natl Acad Sci U S A*. 2008;105(36):13562-7.

- 375 10. Wollenberg A, Wetzel S, Burgdorf WH, Haas J. Viral infections in atopic dermatitis:
376 pathogenic aspects and clinical management. *J Allergy Clin Immunol.* 2003;112(4):667-74.
- 377 11. Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A. Is asthma protective against
378 COVID- 19? *Allergy.* 2020.
- 379 12. Leung DY. Atopic dermatitis: the skin as a window into the pathogenesis of chronic
380 allergic diseases. *J Allergy Clin Immunol.* 1995;96(3):302-18; quiz 19.
- 381 13. Liu Y, Zhang C, Huang F, Yang Y, Wang F, Yuan J, et al. Elevated plasma level of
382 selective cytokines in COVID-19 patients reflect viral load and lung injury. *National Science*
383 *Review.* 2020.
- 384 14. Luo W, Zhang JW, Zhang W, Lin YL, Wang Q. Circulating Levels of IL- 2, IL- 4,
385 TNF- α , IFN- γ and C reactive protein Are Not Associated with Severity of COVID- 19
386 Symptoms. *Journal of Medical Virology.* 2020.
- 387 15. Lucas C, Wong P, Klein J, Castro TB, Silva J, Sundaram M, et al. Longitudinal analyses
388 reveal immunological misfiring in severe COVID-19. *Nature.* 2020;584(7821):463-9.
- 389 16. Fuxench ZCC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, et al. Atopic
390 Dermatitis in America Study: a cross-sectional study examining the prevalence and disease
391 burden of atopic dermatitis in the US adult population. *Journal of Investigative Dermatology.*
392 2019;139(3):583-90.
- 393 17. Dermaotlogy AAo. GUIDANCE ON THE USE OF IMMUNOSUPPRESSIVE AGENTS
394 AAD.org2020 [
- 395 18. Rheumatology ACo. COVID-19 Clinical Guidance for Adult Patients with Rheumatic
396 Diseases. *Rheumatology.org*2020.

- 397 19. Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G. Risk of
398 hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis
399 receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive
400 treatment. *Journal of the American Academy of Dermatology*. 2020;83(1):285-7.
- 401 20. Holcomb ZE, Santillan MR, Morss-Walton PC, Salian P, Her MJ, Giannotti NM, et al.
402 Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy.
403 *Journal of the American Academy of Dermatology*. 2020;83(4):1215-8.
- 404 21. Neurath MF. Covid-19 and immunomodulation in IBD. *Gut*. 2020;69(7):1335-42.
- 405 22. Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, et al. Dupilumab
406 Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. *J Allergy Clin*
407 *Immunol Pract*. 2020;8(2):516-26.
- 408 23. Guttman-Yassky E, Bissonnette R, Ungar B, Suarez-Farinas M, Ardeleanu M, Esaki H, et
409 al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with
410 atopic dermatitis. *J Allergy Clin Immunol*. 2019;143(1):155-72.
- 411 24. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and
412 safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY
413 NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-
414 blind, placebo-controlled, parallel-group phase 3 trials. *Lancet*. 2019;394(10209):1638-50.
- 415 25. He H, Olesen CM, Pavel AB, Clausen M-L, Wu J, Estrada Y, et al. Tape-strip proteomic
416 profiling of atopic dermatitis on dupilumab identifies minimally invasive biomarkers. *Frontiers*
417 *in Immunology*. 2020;11:1768.
- 418 26. Patrino C, Stingeni L, Fabbrocini G, Hansel K, Napolitano M. Dupilumab and COVID-
419 19: What should we expect? *Dermatol Ther*. 2020:e13502.

27. Ferrucci S, Romagnuolo M, Angileri L, Berti E, Tavecchio S. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports. *J Eur Acad Dermatol Venereol.* 2020;34(7):e303-e4.
28. Caroppo F, Biolo G, Belloni Fortina A. SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab. *J Eur Acad Dermatol Venereol.* 2020.
29. Rossi M, Rovati C, Arisi M, Soglia S, Calzavara-Pinton P. Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience. *Dermatol Ther.* 2020:e13765.
30. Napolitano M, Patruno C, Ruggiero A, Nocerino M, Fabbrocini G. Safety of dupilumab in atopic patients during COVID-19 outbreak. *J Dermatolog Treat.* 2020:1-2.
31. Carugno A, Raponi F, Locatelli A, Vezzoli P, Gambini D, Di Mercurio M, et al. No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area- Bergamo, Lombardy, Italy. *Journal of the European Academy of Dermatology and Venereology.* 2020.
32. Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19 severity and fatality: a structured literature review. *Infection.* 2020:1-14.
33. Cortinovis M, Perico N, Remuzzi G. Long-term follow-up of recovered patients with COVID-19. *The Lancet.* 2021;397(10270):173-5.
34. Di Fusco M, Shea KM, Lin J, Nguyen JL, Angulo FJ, Benigno M, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. *Journal of Medical Economics.* 2021:1-.

35. Gittler JK, Shemer A, Suarez-Farinas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQ, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. *J Allergy Clin Immunol*. 2012;130(6):1344-54.
36. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes Jr SJ, Calatroni A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. *Journal of Allergy and Clinical Immunology*. 2015;136(6):1476-85.
37. Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. *J Allergy Clin Immunol*. 2014;133(6):1626-34.
38. Tintle S, Shemer A, Suarez-Farinas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. *J Allergy Clin Immunol*. 2011;128(3):583-93 e1-4.
39. Brunner PM, Khattri S, Garcet S, Finney R, Oliva M, Dutt R, et al. A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. *J Allergy Clin Immunol*. 2016;138(1):169-78.

Table 1. Demographics and symptom severity for all patients and treatment groups.**1A.**

	All patients		Dupilumab	Other systemics	Limited/no treatment	P-value
Sample size (n)	1237		632	107	498	
Age (mean, SD)			41.2 (19.1)	42.0 (19.4)	39.9 (18.9)	0.39
Gender						0.001
Male (n,%)	521 (42%)		296 (47%)	44 (41%)	181 (36%)	
Female (n,%)	716 (58%)		336 (53%)	63 (59%)	317 (64%)	
Race						0.46
American Indian/Alaska Native (n,%)	5 (0.4%)		1 (0.0001%)	0 (0%)	4 (1%)	
Asian (n,%)	216 (17%)		126 (20%)	21 (20%)	69 (14%)	
Black or African American (n,%)	205 (17%)		102 (16%)	18 (17%)	85 (17%)	
Mixed race (n,%)	40 (3%)		21 (3%)	3 (3%)	16 (3%)	
Native Hawaiian/Other Pacific Islander (n,%)	4 (0.3%)		2 (0.0001%)	0 (0%)	2 (0.0001%)	

Unknown (n,%)	95 (8%)		44 (7%)	7 (7%)	44 (9%)	
White (n,%)	672 (54%)		336 (53%)	58 (54%)	278 (56%)	
Comorbidities						
Hypertension			115 (18%)	20 (19%)	72 (14%)	0.21
Diabetes			37 (6%)	7 (7%)	26 (5%)	0.78
Asthma			250 (40%)	38 (36%)	169 (34%)	0.16
Obesity (BMI>30)			112 (20%)	14 (16%)	85 (19%)	0.61
Other medications						
ACEi			20 (3%)	4 (4%)	8 (2%)	0.16
COVID-19 infection						
Laboratory confirmed COVID-19 infection	87 (7%)		39 (6%)	11 (10%)	37 (7%)	0.26

459

460

461

1B. Percentage of patients by COVID-19 symptom severity score in each treatment group.

COVID-19 symptom severity defined as a 5-level score: 0 “asymptomatic”; 1: “mild disease” (no fever, no dyspnea, resolving in <7 days, resembling a common cold); 2: “moderate disease” (some fever and/or cough, or other lower respiratory symptoms, resolving at home in 7-14 days); 3: “severe disease” (pneumonia, required hospitalization, but resolved without intubation); 4-5: “very severe disease” (required hospitalization, intubation, and other supportive measures) or “fatal.”

	All patients n=1233	Dupilumab n=631	Other systemics n=107	Limited/no treatment n=495
Severity				
0 (n, %)	947 (77%)	492 (78%)	73 (68%)	382 (77%)
1 (n, %)	204 (16%)	110 (17%)	18 (17%)	76 (15%)
2 (n,%)	78 (6%)	29 (5%)	15 (14%)	34 (7%)
3 (n,%)	4 (0.3%)	0 (0%)	1 (1%)	3 (1%)
4/5 (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Table 2. Logistic Regression Models Comparing Symptom Severity Among All Patients in Different Treatment Groups.

A. Logistic regression model predicting asymptomatic/mild versus moderate-to-severe symptoms using treatment: Systemics vs Dupilumab as a predictor variable and adjusting for other clinical variables; **B.** Logistic regression model predicting asymptomatic/mild versus moderate-to-severe symptoms using treatment: Limited/No-treatment vs Dupilumab as a predictor variable and adjusting for other clinical variables; **C.** Logistic regression model predicting asymptomatic versus symptomatic using treatment: Systemics vs Dupilumab as a predictor variable and adjusting for other clinical variables; **D.** Logistic regression model predicting asymptomatic versus symptomatic using treatment: Limited/No-treatment vs Dupilumab as a predictor variable and adjusting for other clinical variables. Log Odds Ratio is reported as the natural log of the odds ratio in the logistic regression model.

Outcome	Asymptomatic/mild versus moderate-to-severe symptoms			
	Log Odds Ratio	Standard Error	Z-score	P-value
Intercept	-3.86	2.36	-1.64	0.10
Systemics	1.36	0.51	2.66	0.008
Age	0.01	0.01	0.87	0.39
Asthma	-0.61	0.45	-1.36	0.17
Gender	-0.35	0.45	-0.78	0.43
Hypertension	-1.15	0.75	-1.53	0.12
Diabetes	0.75	0.90	0.83	0.41

BMI	0.13	0.04	3.41	0.001
ACEi	0.55	1.91	0.29	0.77
Race	0.07	0.10	0.63	0.53

491

492 **B**

Outcome	Asymptomatic/mild versus moderate-to-severe symptoms			
	Log Odds Ratio	Standard Error	Z-score	P-value
Intercept	-3.59	1.58	-2.28	0.02
Limited/no treatment	0.67	0.33	2.04	0.04
Age	0.03	0.01	2.46	0.01
Asthma	0.26	0.33	0.79	0.43
Gender	-0.03	0.34	-0.08	0.94
Hypertension	-0.96	0.58	-1.67	0.09
Diabetes	-0.09	0.72	-0.13	0.90
BMI	0.04	0.03	1.55	0.12
ACEi	0.83	1.09	0.76	0.45
Race	-0.07	0.08	-0.85	0.39

493

494 **C**

Outcome	Asymptomatic versus symptomatic			
	Log Odds Ratio	Standard Error	Z-score	P-value
Intercept	-0.59	0.97	-0.60	0.55
Systemics	0.63	0.25	2.46	0.01

Age	-0.001	0.01	-0.28	0.78
Asthma	0.15	0.19	0.77	0.44
Gender	-0.05	0.19	-0.25	0.80
Hypertension	-0.24	0.30	-0.80	0.42
Diabetes	0.16	0.44	0.35	0.72
BMI	0.02	0.02	1.19	0.23
ACEi	-0.74	0.68	-1.08	0.28
Race	-0.11	0.04	-2.50	0.01

495

496 **D**

Outcome	Asymptomatic versus symptomatic			
	Log Odds Ratio	Standard Error	Z-score	P-value
Intercept	-1.32	0.78	-1.70	0.09
Limited/no treatment	0.10	0.15	0.64	0.52
Age	0.001	0.00	0.15	0.88
Asthma	0.27	0.16	1.75	0.08
Gender	-0.09	0.16	-0.56	0.58
Hypertension	-0.38	0.26	-1.46	0.15
Diabetes	0.15	0.36	0.41	0.68
BMI	0.01	0.01	0.67	0.51
ACEi	-0.03	0.54	-0.06	0.95
Race	-0.08	0.04	-2.20	0.03

497

Table 3. Patient demographics in patients with confirmed diagnosis or COVID-19 exposure.

	Dupilumab	Other systemics	Limited/no treatment	P-value
Sample size (n)	164	26	116	
Age (mean, SD)	37.1 (16.7)	42.8 (16.5)	37.6 (15.9)	<0.001
Gender				0.04
Male (n,%)	70 (43%)	9 (35%)	33 (28%)	
Female (n,%)	94 (57%)	17 (65%)	83 (72%)	
Race				0.51
American Indian/Alaska Native (n,%)	0 (0%)	0 (0%)	3 (3%)	
Asian (n,%)	28 (17%)	5 (19%)	13 (11%)	
Black or African American (n,%)	30 (18%)	5 (19%)	19 (16%)	
Mixed race (n,%)	5 (3%)	1 (4%)	5 (4%)	
Native Hawaiian or Other Pacific Islander (n,%)	2 (1%)	0 (0%)	0 (0%)	
Unknown (n,%)	6 (4%)	1 (4%)	9 (8%)	
White (n,%)	93 (57%)	14 (54%)	67 (58%)	
Comorbidities				
Hypertension	21 (13%)	6 (23%)	15 (13%)	0.35

Diabetes	9 (5%)	1 (4%)	5 (4%)	0.91
Asthma	61 (37%)	11 (42%)	44 (38%)	0.89
Obesity (BMI>30)	27 (19%)	7 (30%)	19 (18%)	0.38
Other medications				
ACEi	5 (3%)	0 (0%)	2 (2%)	0.84
COVID exposure and testing				
Tested positive for COVID 19 (n,%)	39 (24%)	11 (42%)	37 (32%)	0.09
Exposure to positive COVID 19 (n,%)	76 (46%)	6 (23%)	46 (40%)	0.06
Exposure to COVID 19-like symptoms (n,%)	49 (30%)	9 (35%)	33 (28%)	0.84

500

501

502

503

504

505

506

Table 4. Logistic Regression Models Comparing Symptom Severity Among Patients with Confirmed Diagnosis or COVID-19 Exposure in Different Treatment Groups.

Within the population of patients with confirmed diagnosis or COVID-19 exposure: **A.** Logistic regression model predicting asymptomatic/mild versus moderate-to-severe symptoms using treatment: Systemics vs Dupilumab as a predictor variable and adjusting for other clinical variables; **B.** Logistic regression model predicting asymptomatic/mild versus moderate-to-severe symptoms using treatment: Limited/No-treatment vs Dupilumab as a predictor variable and adjusting for other clinical variables; **C.** Logistic regression model predicting asymptomatic versus symptomatic using treatment: Systemics vs Dupilumab as a predictor variable and adjusting for other clinical variables; **D.** Logistic regression model predicting asymptomatic versus symptomatic using treatment: Limited/No-treatment vs Dupilumab as a predictor variable and adjusting for other clinical variables. Log Odds Ratio is reported as the natural log of the odds ratio in the logistic regression model.

A

Outcome	Asymptomatic/mild versus moderate-to-severe symptoms			
	Log Odds Ratio	Standard Error	Z-score	P-value
Intercept	-16.59	1455.40	-0.01	0.99
Systemics	2.62	0.86	3.05	0.002
Age	0.04	0.02	1.55	0.12
Asthma	-1.25	0.77	-1.62	0.11
Gender	-0.26	0.66	-0.40	0.69
Hypertension	-2.06	1.15	-1.80	0.07

Diabetes	1.91	1.32	1.44	0.15
BMI	0.22	0.08	2.84	0.005
ACEi	12.09	1455.40	0.01	0.99
Race	-0.11	0.16	-0.70	0.48

522

523 **B**

Outcome	Asymptomatic/mild versus moderate-to-severe symptoms			
	Log Odds Ratio	Standard Error	Z-score	P-value
Intercept	-19.95	1606.87	-0.01	0.99
Limited/no treatment	0.89	0.46	1.94	0.05
Age	0.04	0.02	2.73	0.006
Asthma	0.10	0.46	0.22	0.83
Gender	0.11	0.49	0.23	0.82
Hypertension	-0.97	0.79	-1.22	0.22
Diabetes	-0.87	1.14	-0.76	0.45
BMI	0.08	0.04	1.91	0.06
ACEi	16.70	1606.87	0.01	0.99
Race	-0.05	0.11	-0.43	0.67

524

525 **C**

Outcome	Asymptomatic versus symptomatic			
	Log Odds Ratio	Standard Error	Z-score	P-value
Intercept	0.86	1.86	0.46	0.64

Systemics	1.09	0.51	2.12	0.03
Age	-0.001	0.01	-0.05	0.96
Asthma	0.12	0.34	0.34	0.73
Gender	0.23	0.34	0.68	0.50
Hypertension	0.02	0.54	0.03	0.98
Diabetes	1.00	0.93	1.07	0.28
BMI	-0.03	0.03	-1.06	0.29
ACEi	-1.40	1.44	-0.97	0.33
Race	-0.09	0.08	-1.22	0.22

526

527 **D**

Outcome	Asymptomatic versus symptomatic			
	Log Odds Ratio	Standard Error	Z-score	P-value
Intercept	-0.54	1.41	-0.38	0.70
Limited/no treatment	0.31	0.27	1.18	0.24
Age	0.01	0.01	1.13	0.26
Asthma	0.44	0.27	1.60	0.11
Gender	0.09	0.28	0.32	0.75
Hypertension	-0.41	0.45	-0.92	0.36
Diabetes	0.72	0.66	1.08	0.28
BMI	-0.03	0.02	-1.14	0.25
ACEi	-0.58	0.98	-0.58	0.56
Race	-0.05	0.06	-0.75	0.46

Figure Legends**Figure 1. COVID-19 symptoms in whole patient cohort grouped by treatment.** Whole

patient cohort separated into treatment groups, dupilumab (n=631), other systemics (n=107), and limited/no treatment (n=495), grouping symptom severity by **A.** scores of 0-1 (asymptomatic or mild symptoms) and 2-5 (moderately symptomatic to fatal), and **B.** scores of 0 (asymptomatic) or 1-5 (symptomatic). *P<0.05. **P<0.01.

Figure 2. COVID-19 symptoms in exposed patient cohort grouped by treatment. Cohort of

patients with known infection or high-risk COVID-19 exposures, separated into treatment groups, dupilumab (n=164), other systemics (n=26), and limited/no treatment (n=116), grouping symptom severity by scores of **A.** 0-1 (asymptomatic or mild symptoms) and 2-5 (moderately symptomatic to fatal), and **B.** scores of 0 (asymptomatic) or 1-5 (symptomatic). *P<0.05.

**P<0.01.

Figure 1




Figure 2

